Abeona Therapeutics price target raised to $21 from $14 at Stifel

Stifel analyst Stephen Willey raised the firm’s price target on Abeona Therapeutics (ABEO) to $21 from $14 and keeps a Buy rating on the shares. The firm believes FDA’s broad approval of Zevaskyn for the treatment of wounds in adult/pediatric RDEB patients represents an important milestone which appropriately now transitions focus to the commercial execution of a high-margin business, which Stifel assumes becomes sustainably profitable in FY26. The firm thinks the most important disclosures on management’s post-approval call included higher-than-anticipated Zevaskyn pricing, the planned implementation of outcomes-based arrangements with payers, the indirect issuance of FY25 revenue guidance, and the ability to reach break-even at a modest throughput of 3 patients/month.